# Anthropic Establishes Secretive Biology Lab in Bay Area AI firm expands into physical experiments while keeping purpose under wraps - **Source:** [The Next Web](https://brifing.si/source/afe24b20-b275-4c19-b9a6-8bb3c8babae7) - **Published:** 2026-09-18 - **Topic:** [Data & AI](https://brifing.si/c/data-ai) - **Original article:** - **On Brifing:** https://brifing.si/s/7c49552d-2159-4f8b-8df2-d0e2c321c55e ## Covert biology facility Anthropic has constructed a physical biology laboratory in the San Francisco Bay Area, marking a shift from pure simulation to hands-on experimentation. While confirming the lab's existence, the company remains tight-lipped about its specific purpose beyond stating it's not focused on drug discovery. The facility represents a significant but opaque investment into biological research by an AI company known for its large language models. This development follows Anthropic's growing life sciences division, which has become one of its largest departments by both staffing and budget. ## Strategic acquisitions The lab establishment follows Anthropic's aggressive expansion into biotech through acquisitions. In April 2024, the company purchased Coefficient Bio, a small startup, for approximately $400 million in stock. That same month, Novartis CEO Vas Narasimhan joined Anthropic's Long-Term Benefit Trust board. These moves signal serious commitment to biological research, though the company maintains secrecy about how these pieces fit together. The acquisitions provide both technical capabilities and industry expertise to support Anthropic's mysterious lab operations. ## Claude Science launch Parallel to its physical lab development, Anthropic introduced Claude Science in June 2024 - specialized software for laboratory research rather than conversational applications. Major pharmaceutical companies including Genentech and Bristol Myers Squibb have already adopted the tool, with Novo Nordisk signing on just days before the lab announcement. This dual approach of physical experimentation and specialized AI tools suggests Anthropic is building an integrated biology research platform. The company's life sciences head emphasizes that real-world lab work remains essential despite advances in simulation. ## Deliberate opacity Anthropic has revealed almost nothing about the lab's specifications or operations. Key details like size, staffing levels, opening date, and biosafety certification remain undisclosed. The company continues outsourcing some biological work to external partners, indicating the new facility complements rather than replaces existing arrangements. This secrecy contrasts with Anthropic's typical transparency about its AI capabilities, raising questions about the nature of research being conducted. The biosafety level, if disclosed, would particularly reveal the risk level of experiments permitted. ## Personal motivation Reuters connects part of Anthropic's biological research push to CEO Dario Amodei's personal history. His father died from a disease before effective treatments were developed, potentially influencing the company's direction. This personal dimension adds context to Anthropic's otherwise opaque biological research agenda. The company maintains that its physical lab work is necessary for meaningful biological advancement, though specifics of how it relates to their AI work remain unclear. Amodei's experience may shape the lab's priorities while its exact focus stays secret. ## Risk management concerns Anthropic's biological research raises unique safety questions given its AI expertise. The company has previously identified scenarios where its systems could potentially aid biological weapons development. It recently relaxed some biological safeguards on Claude 5, while simultaneously expanding physical experimentation capabilities. When questioned about balancing innovation and risk, the life sciences head offered vague assurances about careful deployment. This tension between advancing biological research and preventing misuse becomes more tangible with a physical lab handling unknown materials. ## Industry implications Anthropic's move into physical biology experiments blurs traditional boundaries between AI and biotech firms. The company's combination of advanced AI with wet lab capabilities creates a novel research paradigm. Pharmaceutical partners like Genentech and Novo Nordisk may gain early access to resulting innovations. However, the secrecy surrounding the lab's purpose makes it difficult to assess potential impacts on drug discovery, bioengineering, or other life science fields. This development could signal a new model for AI companies expanding beyond digital domains. ## Simulation limits Anthropic's decision to build a physical lab stems from the belief that biological understanding ultimately requires real-world experimentation. The company acknowledges that while AI simulations are powerful tools, they cannot fully replace bench science for the foreseeable future. This philosophy represents a significant departure from purely computational approaches to biological research. The lab embodies Anthropic's warning about over-reliance on simulation, particularly regarding biological systems where physical testing remains crucial. This development may influence how other AI companies approach life sciences research. ## Sources covering this story - https://thenextweb.com/news/anthropic-biology-wet-lab-drug-program — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._